Article Text

Download PDFPDF
Iridotomies on eyes with uveitis: indications and technique
  1. Gary N Holland1,
  2. Keith Barton2
  1. 1 UCLA Stein Eye Institute, Los Angeles, California, USA
  2. 2 Moorfields Eye Hospital, London, UK
  1. Correspondence to Dr Gary N Holland, UCLA Stein Eye Institute, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA; uveitis{at}

Statistics from

Posterior synechiae are common complications of anterior uveitis, and can result in pupillary seclusion, iris bombé and angle-closure. In this issue of the journal, Betts and associates1 describe their experience in managing such patients. Despite the limitations of a non-randomised, retrospective study, their results support the assumption of many uveitis and glaucoma experts that patients with uveitis whose disease is complicated by iris bombé from extensive posterior synechiae should have surgical iridectomies rather than laser iridotomies. The authors’ patients who were managed surgically had a markedly lower risk of treatment failure. Why the difference in outcomes? Laser iridotomies may stimulate more inflammation than surgical iridectomies, causing an outpouring of fibrin from the laser iridotomy site, which will eventually close the small, irregular opening. In contrast, surgical iridectomies are larger; with sharp, well-defined edges; and they tend to be more peripheral, all factors reducing the risk that the opening will scar closed.

Inflammation at the time of the iris procedure was not identified as a significant risk factor for failure in the current authors’ series, …

View Full Text


  • Funding Supported by the Skirball Foundation, New York, NY (Dr. Holland); an unrestricted grant from Research to Prevent Blindness, New York, NY to the UCLA Stein Eye Institute for research (Dr Holland).

  • Competing interests KB: Personal fees—Alcon, Allergan, Laboratoires Thea, Santen, Transcend Medical, Calpain Therapeutics, RhPharma, iStar, Radiance Therapeutics, EydD Pharma, Advanced Ophthalmic Implants; Grants—Allergan, Laboratoires Thea, Merck; Grants and other—Aquesys; other from Vision Futures, Vision Medical Events, International Glaucoma Surgery Registry, and MedEther Ophthalmology.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles